Carl L Gordon bought $15M of SCTX
director at Scribe Therapeutics, Inc.. 1,000,000 shares at an average of $15.00, traded Jul 27, 2026, filed Jul 29, 2026.
Score components
- +15RoleDirector
- +25Trade size$15.0M at market
- +10Relative to holdingsHoldings up 287%
- 0Price contextNo price history yet
- +15Cluster6 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000947871-26-000734, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 27, 2026 | CConversion Common Stockindirect: See footnotes | +348,825 | - | - | 348,825 | Jul 29, 2026 |
| Jul 27, 2026 | POpen-market purchase Common Stockindirect: See footnotes | +1,000,000 | $15.00 | $15M | 1,348,825 | Jul 29, 2026 |
| Jul 27, 2026 | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -2,065,672 | $0.00 | $0 | 0 | Jul 29, 2026 |
Related signals
Other insiders at Scribe Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Scribe Therapeutics, Inc. | AH Bio Fund II, L.P. owner | $5.0M 333,333 shares | +16% | |
| 60Notable | Scribe Therapeutics, Inc. | Orbimed Advisors LLC director | $15M 1,000,000 shares | +287% | |
| 65Notable | Scribe Therapeutics, Inc. | Behzad Aghazadeh director, owner, other | $36M 2,391,238 shares | +343% | |
| 44Moderate | Scribe Therapeutics, Inc. | Svetlana Lucas Chief Business Officer | $45k 3,000 shares | - | |
| 51Moderate | Scribe Therapeutics, Inc. | David Parrot Chief Financial Officer | $40k 2,666 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.